Nearly 4,000 Bard PowerPort Lawsuits Are Awaiting Outcome of Upcoming Bellwether Trials

Port catheters are subdermal medical devices consisting of an injection port connected to a polyurethane catheter, commonly implanted in patients requiring regular intravenous access such as those undergoing chemotherapy. The devices are designed to allow medical professionals to administer drugs and fluids without repeated needle punctures.

Plaintiffs allege that Bard PowerPort devices contain manufacturing and design defects despite being marketed as safe and effective. Alleged failures include catheter fracture and migration, with fragments potentially entering the bloodstream. Reported injuries associated with the devices include infections, pulmonary embolisms, blood clots, and death.

Over 3,700 product liability lawsuits have been filed against C.R. Bard and its parent company Becton Dickinson. The litigation includes a series of bellwether trials designed to test key evidence and testimony and inform settlement discussions. A second bellwether trial is scheduled to commence in mid-August 2026.

This is a curated brief from the PlaintiffWire news desk. Read the original report at AboutLawsuits.